Replies to post #3144 on Momenta Pharmaceuticals, Inc. (MNTA)

[Double_Bagel]

Patrick, when did Canaccord come out with their price target? Was this during or after market hours. If it did during market hours, then it had no effect on MNTA today. How come there is nothing about either UBS or Canaccord's coverage on Yahoo?

You know what is going to happen for next quarter? All these idiotic analysts will raise their estimate for next quarter to around $1.10-$1.15 and if MNTA does not beat it, that might send the stock price down. If it does beat it, they will say, so what T-Enox is coming. Can't win either way :-(

[IB2011]

I think this all goes back do Dew's belief that efficient markets are nonsense.

Canaccord is egregiously wrong on several important points. First,the MNTA profit share is more like $78-80 million on an ongoing basis, not $60 million.

Second, Canaccord's guess about approval of T-Enox in Q4 2011 is inconsistent with a price target of $27. If he believes his approval date, he should cut his target.

By the way, UBS says approval of T-Enox will come in July 2011. What a wonderful crystal ball he must have. Or he heard this from a little birdie named TEVA.

Not much fun ending the week this way.

[DewDiligence]

According to a prominent sell-side analyst who follows MNTA, every sell-side analyst on Wall Street understands that Teva’s Lovenox is DoA, but these analysts are unwilling to say so in print for fear of losing IB business from Teva.

[alertmeipp]

Lovenox, Lovenox, Lovenox - hope we have something else to talk about soon.